Omega Pharma

Omega Pharma was a Belgian consumer-healthcare company founded in 1987 by Marc Coucke and Yvan Vindevogel, former pharmacy students at Ghent University. The business began with a simple pharmacist-oriented product: shampoo supplied in five-litre containers, which pharmacists could customize with their own fragrance and colour for sale under local or in-house labels. This early model gave Omega Pharma a close relationship with pharmacies and helped establish the company as a supplier of consumer products distributed through professional healthcare channels. The company broadened its portfolio in 1989 with Uvesol tanning lotions and subsequently built a wide range of over-the-counter, self-care, personal-care, nutritional, and medical-device brands. Its products covered areas including cough and cold care, nasal sprays, dermatology, baby skincare, intimate hygiene, vitamins and minerals, aromatherapy, pregnancy testing, lice treatment, wart removal, weight management, menopause support, and cosmetics. Brands associated with the company included Biodermal, Biover, Bodysol, Bronchostop Duo, Davitamon, Dermalex, Galenco, Lactacyd, Paranix, Physiomer, Predictor, T. LeClerc, Wartner, Ymea, and several others. The precise ownership of individual brands has changed over time, particularly following the Perrigo transaction, so the historical association with Omega Pharma should not automatically be read as current ownership. Omega Pharma initially operated as a privately held company owned equally by its two founders. In 1994, Vindevogel sold his shares to Coucke, leaving Coucke as the controlling shareholder. Omega Pharma completed an initial public offering in 1998 and became listed on Euronext Brussels. It was included in the BEL20 index for a period, reflecting its importance in the Belgian equity market. In late 2011, however, Coucke's investment vehicle Couckinvest and private-equity firm Waterland took the company private again. The group also reorganized its professional-health activities. At Omega Pharma's 2006 annual shareholders meeting, management announced that this division would operate under the name Arseus. Arseus was subsequently separated from Omega Pharma and became an independent company through an IPO on 5 October 2007, with listings on the Brussels and Amsterdam markets. This separation distinguished Omega Pharma's consumer-healthcare activities from a professional-health platform serving healthcare practitioners and related businesses. Omega Pharma also developed visibility outside pharmacies through sports sponsorship. From 2012 to 2014, it co-sponsored the professional cycling team Omega Pharma–Quick-Step with the Quick-Step flooring brand. The sponsorship connected the company with an internationally visible Belgian-led cycling property and provided a platform for consumer brand promotion. Perrigo agreed to acquire Omega Pharma, and the transaction became effective on 31 March 2015. Following the acquisition, Omega Pharma ceased to operate as an independent public company and its activities were incorporated into Perrigo's branded consumer-healthcare operations. Omega Pharma is therefore best understood today as a historical Belgian corporate brand and former operating group whose portfolio and commercial legacy continue through brands and businesses associated with Perrigo, rather than as a standalone company.

Omega Pharma was established in Belgium in 1987 by Marc Coucke and Yvan Vindevogel, who had studied pharmacy at Ghent University. The founders initially held equal stakes. Their first commercial product was shampoo packaged in five-litre containers and sold to pharmacists, who could add a fragrance and colour and market it as a locally customized product. In 1989, the company expanded into tanning products with Uvesol. In 1994, Vindevogel sold his shares to Coucke. Omega Pharma subsequently developed into a broad consumer-healthcare group with strong links to pharmacies and self-medication markets. Its portfolio covered over-the-counter medicines, nutritional supplements, dermatology, personal care, intimate hygiene, baby care, aromatherapy, cosmetics, diagnostic tests, and home treatments. The group accumulated or marketed numerous brands, including Davitamon, Physiomer, Wartner, Paranix, Lactacyd, Biodermal, Biover, Dermalex, Predictor, Ymea, and T. LeClerc. Omega Pharma entered the public markets in 1998 through an IPO on Euronext Brussels. It was later included in the BEL20 index. The company also created a separate professional-health platform. At the annual shareholders meeting in June 2006, it announced that this division would operate as Arseus. Arseus was prepared for autonomy and became an independent listed company through an IPO on 5 October 2007, with trading on the Brussels and Amsterdam exchanges. The public-company phase ended in late 2011, when Coucke's investment company Couckinvest and Waterland acquired the shares needed to take Omega Pharma private. The group continued to build consumer visibility through sponsorship, including its co-sponsorship with Quick-Step of the Omega Pharma–Quick-Step cycling team from 2012 through 2014. Perrigo acquired Omega Pharma, with the transaction becoming effective on 31 March 2015. After the acquisition, Omega Pharma was incorporated into Perrigo's Branded Consumer Healthcare division. It consequently no longer exists as an independent listed company, although products and brands historically connected with the company may continue under Perrigo or other subsequent ownership arrangements.

• 2015

  Perrigo acquisition becomes effective

  [1]Omega Pharmaen.wikipedia.org

  Perrigo completes its acquisition of Omega Pharma on 31 March, integrating it into branded consumer healthcare.

• 2012

  Cycling sponsorship begins

  [1]Omega Pharmaen.wikipedia.org

  Omega Pharma becomes a co-sponsor of the Omega Pharma–Quick-Step professional cycling team.

• 2011

  Company taken private

  [1]Omega Pharmaen.wikipedia.org

  Couckinvest and Waterland take Omega Pharma private after its period as a public company.

• 2007

  Arseus completes its IPO

  [1]Omega Pharmaen.wikipedia.org

  Arseus becomes an independent company through an IPO on 5 October, with Brussels and Amsterdam listings.

• 2006

  Arseus separation announced

  [1]Omega Pharmaen.wikipedia.org

  Omega Pharma announces that its professional-health division will operate as Arseus and prepare for independence.

• 1998

  Initial public offering

  [1]Omega Pharmaen.wikipedia.org

  Omega Pharma lists on Euronext Brussels.

• 1994

  Vindevogel exits the shareholding

  [1]Omega Pharmaen.wikipedia.org

  Yvan Vindevogel sells his shares to Marc Coucke, who becomes the controlling shareholder.

• 1989

  Uvesol tanning products introduced

  [1]Omega Pharmaen.wikipedia.org

  The company expands beyond its initial shampoo business by beginning sales of Uvesol tanning lotions.

• 1987

  Omega Pharma is founded

  [1]Omega Pharmaen.wikipedia.org

  Marc Coucke and Yvan Vindevogel establish Omega Pharma in Belgium and initially own equal shares.

A pharmacy-oriented European consumer-healthcare group offering accessible self-care, wellness, personal-care, and over-the-counter products across multiple everyday health categories.

• Vitamins and nutritional supplements

  Davitamon

  Davitamon was one of Omega Pharma's vitamin and multivitamin brands. Its positioning centered on everyday nutritional supplementation and products designed for different consumer needs and life stages. The brand formed part of Omega Pharma's broader pharmacy and consumer-wellness portfolio.

• Nasal care

  Physiomer

  Physiomer is associated with nasal sprays made from purified seawater. It represented Omega Pharma's self-care approach to nasal hygiene and congestion-related needs, fitting the company's emphasis on accessible products distributed through pharmacies and other healthcare channels.

• Home dermatological treatment

  Wartner

  Wartner was a home-use wart-removal brand in Omega Pharma's consumer-healthcare portfolio. It illustrates the company's focus on products that allow consumers to manage common, generally non-prescription conditions outside a clinical setting.

• Lice treatment

  Paranix

  Paranix was marketed for head-lice care and prevention. The brand occupied a practical family-health niche within Omega Pharma's wider range of home treatments and pharmacy products.

• Skincare

  Biodermal

  Biodermal was a skincare brand associated with Omega Pharma. It contributed to the group's dermatology and personal-care presence alongside brands aimed at sensitive, dry, or otherwise specific skin needs.

• Intimate hygiene

  Lactacyd

  Lactacyd was part of Omega Pharma's female intimate-hygiene portfolio. Its inclusion reflected the company's strategy of addressing everyday personal-care needs through pharmacy-accessible consumer brands.

• Pregnancy testing

  Predictor

  Predictor was a pregnancy-test brand in Omega Pharma's self-diagnostic product range. It extended the company's activities beyond medicines and supplements into at-home health testing.

• Menopause support

  Ymea

  Ymea was positioned around products intended to reduce symptoms associated with menopause. It represented Omega Pharma's use of targeted consumer-health brands for specific stages and conditions in consumers' lives.

• Natural healthcare

  Biover

  Biover covered natural-health products including vitamins, minerals, supplements, and aromatherapy-related offerings. The brand complemented Omega Pharma's conventional self-care products with a wellness and botanical orientation.

• Dermatological skincare

  Dermalex

  Dermalex was associated with skincare for ordinary skin concerns and specific dermatological conditions. It occupied the boundary between personal care and condition-focused consumer healthcare within Omega Pharma's portfolio.

• 2012Omega Pharma–Quick-Step cycling sponsorship

  Belgium · Europe · International cycling audiences

  Omega Pharma and Quick-Step jointly sponsored a UCI World Tour professional cycling team from 2012 through 2014. The sponsorship gave Omega Pharma a high-profile sports-marketing platform and associated the corporate name with an internationally followed Belgian cycling team.

  Outcome. The team competed under the Omega Pharma–Quick-Step name during the sponsorship period; the arrangement ended after 2014.

  Source

• 2015

  Acquisition by PerrigoM&A

  Background

  Perrigo pursued Omega Pharma as a major addition to its international branded consumer-healthcare activities.

  Action taken

  Perrigo completed the acquisition with effect from 31 March 2015.

  Aftermath

  Omega Pharma was integrated into Perrigo's Branded Consumer Healthcare division and no longer operated as an independent listed company.

  Source

• 2011

  Return to private ownershipStrategy

  Background

  After trading publicly on Euronext Brussels and participating in the BEL20 index, Omega Pharma underwent a change in ownership structure.

  Action taken

  Couckinvest and Waterland took the company private.

  Aftermath

  Omega Pharma ceased to be an independent public company and continued as a privately controlled consumer-healthcare group until its acquisition by Perrigo.

  Source

• 2006

  Separate the professional-health division as ArseusStrategy

  Background

  Omega Pharma's professional-health activities were being organized separately from its consumer-healthcare operations.

  Action taken

  Management announced the Arseus name and prepared the division for independent operation and a later public listing.

  Aftermath

  Arseus became an independent company through an IPO in October 2007.

  Source

1. 1Omega Pharmaen.wikipedia.org
2. 2Perrigo Company plcperrigo.com